BridgeBio Oncology Therapeutics to Participate in Key Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 /CourierPR/ -- BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, will have key leadership members participate in several prominent investor conferences in September 2026, as announced today.

BBOT will present at the following events: - Cantor Global Healthcare Conference 2026 on September 9, 2026, at 9:45 a.m. Eastern Time. - Citi's 2026 Biopharma Back to School Conference on September 10, 2026, at 3:00 p.m. Eastern Time. - Morgan Stanley's 24th Annual Global Healthcare Conference on September 15, 2026, at 1:50 p.m. Eastern Time.

Live webcasts of the presentations will be available on the "Events" page of BBOT’s investor website, accessible at https://investors.bbotx.com/news-events/events. Replays will remain available for at least 90 days post-conference.

BridgeBio Oncology Therapeutics aims to develop next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.